MARKET

LXRX

LXRX

Lexicon Pharmaceuticals Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.740
+0.060
+3.57%
After Hours: 1.710 -0.03 -1.72% 16:17 05/27 EDT
OPEN
1.680
PREV CLOSE
1.680
HIGH
1.790
LOW
1.640
VOLUME
350.10K
TURNOVER
0
52 WEEK HIGH
6.33
52 WEEK LOW
1.560
MARKET CAP
260.29M
P/E (TTM)
-2.8385
1D
5D
1M
3M
1Y
5Y
Lexicon Pharmaceuticals: Q1 Earnings Insights
  Lexicon Pharmaceuticals (NASDAQ:LXRX) reported its Q1 earnings results on Thursday, May 5, 2022 at 06:00 AM. Here's what investors need to know about the announcement.
Benzinga · 05/05 12:03
BRIEF-Lexicon Pharmaceuticals Reports Qtrly Loss Per Share $0.16
reuters.com · 05/05 11:22
Lexicon Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Clinical Update
Conference Call and Webcast at 8:00 am Eastern TimeTHE WOODLANDS, Texas, May 05, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended March 31, 2022 and provided an update on key...
GlobeNewswire · 05/05 10:00
Lexicon Pharmaceuticals to Host First Quarter 2022 Financial Results Conference Call and Webcast on May 5, 2022
THE WOODLANDS, Texas, April 29, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its first quarter 2022 financial results on Thursday, May 5, 2022 before the markets open. Management will conduct a conference call and liv...
GlobeNewswire · 04/29 12:00
Lexicon Pharmaceuticals To Participate In The 21st Annual Needham Virtual Healthcare Conference
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that Jeffrey L. Wade, Lexicon's president and chief financial officer, will present at the 21st Annual Needham Virtual Healthcare Conference on
Benzinga · 04/07 12:15
Lexicon Pharmaceuticals to Participate in the 21st Annual Needham Virtual Healthcare Conference
THE WOODLANDS, Texas, April 07, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Jeffrey L. Wade, Lexicon’s president and chief financial officer, will present at the 21st Annual Needham Virtual Healthcare Conferen...
GlobeNewswire · 04/07 12:00
Lexicon Touts New Favorable Data On Sotaglifozin Cardio Data
Benzinga · 04/04 13:15
Lexicon Welcomes New Guidelines for the Management of Heart Failure
Guidelines issued jointly by the American Heart Association, American College of Cardiology and Heart Failure Society of America New guidelines recommend the use of SGLT inhibitors for the prevention and treatment of heart failure and highlight the need to...
GlobeNewswire · 04/04 12:00
More
No Data
Learn about the latest financial forecast of LXRX. Analyze the recent business situations of Lexicon Pharmaceuticals Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

33.33%Strong Buy
0.00%Buy
66.67%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average LXRX stock price target is 18.00 with a high estimate of 18.00 and a low estimate of 18.00.
High18.00
Average18.00
Low18.00
Current 1.740
EPS
Actual
Estimate
-0.14-0.11-0.07-0.04
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 166
Institutional Holdings: 125.76M
% Owned: 84.07%
Shares Outstanding: 149.59M
TypeInstitutionsShares
Increased
33
2.16M
New
7
336.90K
Decreased
37
2.39M
Sold Out
15
1.45M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.72%
Pharmaceuticals & Medical Research
+1.28%
Key Executives
Non-Executive Chairman/Independent Director
Raymond Debbane
President/Chief Financial Officer
Jeffrey Wade
Chief Executive Officer/Director
Lonnel Coats
Executive Vice President
Alan Main
Senior Vice President/General Counsel
Brian Crum
Senior Vice President
Craig Granowitz
Senior Vice President
Kenneth Kassler-Taub
Vice President - Finance
Kristen Alexander
Vice President/Director of Human Resources
Wendy Mcdermott
Vice President
Kiernan Seth
Independent Director
Philippe Amouyal
Independent Director
Samuel Barker
Independent Director
Robert Lefkowitz
Independent Director
Alan Nies
Independent Director
Frank Palantoni
Independent Director
Christopher Sobecki
Independent Director
Judith Swain
No Data
No Data
About LXRX
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of treatments for human diseases. The Company's drug programs include Sotagliflozin, LX9211 and LX2761. LX9211 is an orally-delivered small molecule compound that is being developed for the treatment of neuropathic pain. The Company is conducting a Phase II clinical trial of LX9211 in diabetic peripheral neuropathic pain and a second Phase II clinical trial of LX9211 in post-herpetic neuralgia. Sotagliflozin is an orally-delivered small molecule compound that is being developed for the treatment of type I diabetes and type II diabetes, heart failure and chronic kidney disease. LX2761 is an orally-delivered small molecule compound that is designed to inhibit sodium-glucose cotransporter 1 (SGLT1) locally in the gastrointestinal tract without any inhibition of sodium-glucose cotransporter 2 (SGLT2) in the kidney.

Webull offers kinds of Lexicon Pharmaceuticals, Inc. stock information, including NASDAQ:LXRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LXRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LXRX stock methods without spending real money on the virtual paper trading platform.